Less than one in 10 individuals who could benefit from obesity jabs including Wegovy can access them, caution the global health agency as it publishes its first guidance on the therapies.
Considering over a billion people worldwide currently obese, it is urging more widespread and fairer access to these injectable treatments.
Based on projections, more than two billion could be obese by 2030 unless action is taken.
"The latest guidance acknowledges that excess weight is a chronic disease that can be treated with comprehensive and ongoing treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and distribution challenges are significant obstacles to broad access to the jabs that can help people shift substantial weight, explains the organization.
Weight-Loss Drug Supply Crisis
Even under the current best projected outlook, the production of these medications might only reach about 100 million people – fewer than 10% of the global need, as stated by the WHO.
The recommendation calls on countries and companies to increase availability, by measures like voluntary licensing.
A patent on a key compound – the primary ingredient of the drug Wegovy – is due to expire in multiple nations in 2026.
How Weight-Loss Drugs Work
These medications mimick a biological compound to delay gastric emptying, curb appetite and boost satiety so users eat less.
Individuals typically begin shedding pounds after several weeks of beginning the weekly injections.
Studies points to patients may see weight return after a year of discontinuing the drug, because their typical food cravings return.
To be carrying excess weight raises your risk for experiencing health problems, including type 2 diabetes, heart disease, brain attack, and certain cancers.
Obesity affects people in every country and was associated with millions of fatalities worldwide in 2024, as per the health agency.
